{"anticipatedPostingDate":"2027-03","denomUnitsSelected":"Participants","description":"Data for this outcome measure will be reported after study completion (anticipated study completion date is March 2026)","reportingStatus":"NOT_POSTED","timeFrame":"Cycles 1 and 2 Day 1; 0.5-4 hours and 6-10 hours postdose; Cycle 1 Day 15: predose and 2-12 hours postdose; Cycles 3, 4, 5 and 6 Day 1: predose (Cycle length=21 days)","title":"Model-predicted Clearance for Lenvatinib and Everolimus","type":"SECONDARY"}